Study Overview: This study is testing a new medicine called MRTX849 (adagrasib) for patients with advanced solid tumors, like lung or colon cancer, that have a special change in their genes called a KRAS G12C mutation. A mutation means the gene has changed in a way that might cause cancer to grow. MRTX849 is a pill that blocks the effects of the KRAS G12C mutation.

Key Points:

• The study checks how safe the drug is and how well it works in the body.
• Participants will need to have cancer that cannot be removed by surgery or has spread to other parts of the body.
• People who can't take pills or have other active cancer cannot join the study.

Who Can Join: To join, you need to have a confirmed diagnosis of a tumor with a KRAS G12C mutation, and you cannot have other active cancers. You also need to have working organs and should not have other conditions like intestinal diseases that affect swallowing or digestion.